Dillione Janet sells CorMedix (CRMD) shares for $342,600

CorMedix Director Janet Dillione sold 30,000 shares on Nov. 14 at $11.41–$11.44 (weighted avg. $11.42) for about $342,600 and now owns 48,473 shares; the sale was executed above the current market price of $10.07, which is down roughly 12% over the past week. The transaction comes alongside a strong Q3 2025 beat—EPS $1.26 vs. $0.43 expected (193% surprise) and revenue $104.3M vs. $65.9M expected—plus very high gross margins (~94.3%) and analyst price targets of $14–$22, a combination that highlights robust fundamentals despite recent share weakness and suggests potential upside if market sentiment normalizes.

Analysis

Director Janet Dillione sold 30,000 shares of CorMedix (CRMD) on November 14 at $11.41–$11.44 (weighted avg. $11.42), netting roughly $342,600, and now directly owns 48,473 shares; that sale was executed above the current market price of $10.07, which has declined nearly 12% over the past week. The transaction occurred alongside a very strong operational quarter: Q3 2025 EPS of $1.26 versus $0.43 expected (193% surprise) and revenue of $104.3 million versus $65.9 million expected, while gross margins are reported at an unusually high 94.3% and the company is expected to remain profitable this year. Analysts maintain a bullish consensus with price targets between $14 and $22, implying potential upside of approximately 39%–118% from today's price, yet the stock’s recent pullback despite the beat signals either profit-taking or investor skepticism about sustainability. The insider sale at a premium to the current price suggests opportunistic liquidity rather than immediate capitulation — investors should therefore monitor follow‑through on revenue and margin sustainability, future guidance, and any pattern of additional insider transactions as the primary catalysts for revising conviction.

Key Decisions for Investors

• Consider a selective, modest long position given the strong Q3 beat, 94.3% gross margins, and analyst targets implying 39%–118% upside, but avoid full-sized exposure on the initial rebound
• Delay increasing position size until management confirms sustainability of revenue and margins in upcoming commentary or subsequent quarters, monitor Q4 guidance and sales drivers closely
• Watch insider filing activity for further sales or purchases — a one-off sale executed above the current price is not a clear negative signal, but a pattern would warrant reevaluation
• Employ risk controls such as position limits, a stop-loss, or option-based hedges to protect against further short-term volatility following the ~12% weekly decline